Delving into the Latest Updates on Chengdu Kanghong Biotechnologies Co., Ltd. with Synapse

Overview

Tags

Eye Diseases

Neoplasms

Cardiovascular Diseases

Fc fusion protein

Dual payload Antibody drug conjugate (Dual payload ADC)

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Dual payload Antibody drug conjugate (Dual payload ADC)	2
Biological products	1
Fc fusion protein	1

Top 5 Target	Count

POLR2A x Top I x Trop-2	1
HER3(Receptor tyrosine-protein kinase erbB-3)	1
VEGF-A(Vascular endothelial growth factor A)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

2

IND Approval

Phase 2

2

1

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Conbercept ( VEGF-A )	Wet age-related macular degeneration More	Approved
KH815 ( POLR2A x Top I x Trop-2 )	Advanced Malignant Solid Neoplasm More	Phase 1/2
KHN922 ( HER3 )	Advanced Malignant Solid Neoplasm More	Phase 1/2
Dupilumab Biosimilar (Chengdu Kanghong Biotechnologies Co., Ltd.) ( IL-13 x IL-4 )	Dermatitis, Atopic More	IND Approval
KH813 ( PD-1 )	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma More	IND Approval